Eric L Grogan

Dr. Eric L Grogan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
MSMaren E. Shipe
Maren E. Shipe
SDStephen A. Deppen
Stephen A. Deppen
FFFarhood Farjah
Farhood Farjah
EGEric L Grogan
Eric L Grogan
Prediction models help healthcare professionals and patients make clinical decisions. The goal of an accurate prediction model is to provide patient risk stratification to support tailored clinical decision-making with the hope of improving patient outcomes and quality of care. Clinical prediction models use variables selected because they are thought to be associated (either negatively or positively) with the outcome of interest. Building a model requires data that are computer-interpretable and reliably recorded within the time frame of interest for the prediction. Such models are generally defined as either diagnostic, likelihood of disease or disease group classification, or prognostic, likelihood of response or risk of recurrence. We describe a set of guidelines and heuristics for clinicians to use to develop a logistic regression-based prediction model for binary outcomes that is intended to augment clinical decision-making.

1 December 2021 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MKMichael Nolan Kammer
Michael Nolan Kammer
DLDhairya A Lakhani
Dhairya A Lakhani
ABAneri B. Balar
Aneri B. Balar
SASanja L. Antic
Sanja L. Antic
AKAmanda K. Kussrow
Amanda K. Kussrow
PMPierre P. Massion
Pierre P. Massion
Rationale: Patients with indeterminate pulmonary nodules (IPNs) at risk of cancer undergo high rates of invasive, costly, and morbid procedures. Objectives: To train and externally validate a risk prediction model that combined clinical, blood, and imaging biomarkers to improve the noninvasive management of IPNs. Methods: In this prospectively collected, retrospective blinded evaluation study, probability of cancer was calculated for 456 patient nodules using the Mayo Clinic model, and patients were categorized into low-, intermediate-, and high-risk groups. A combined biomarker model (CBM) including clinical variables, serum high sensitivity CYFRA 21-1 level, and a radiomic signature was trained in cohort 1 (n = 170) and validated in cohorts 2–4 (total n = 286). All patients were pooled to recalibrate the model for clinical implementation. The clinical utility of the CBM compared with current clinical care was evaluated in 2 cohorts. Measurements and Main Results: The CBM provided improved diagnostic accuracy over the Mayo Clinic model with an improvement in area under the curve of 0.124 (95% bootstrap confidence interval, 0.091–0.156; P < 2 × 10−16). Applying 10% and 70% risk thresholds resulted in a bias-corrected clinical reclassification index for cases and control subjects of 0.15 and 0.12, respectively. A clinical utility analysis of patient medical records estimated that a CBM-guided strategy would have reduced invasive procedures from 62.9% to 50.6% in the intermediate-risk benign population and shortened the median time to diagnosis of cancer from 60 to 21 days in intermediate-risk cancers. Conclusions: Integration of clinical, blood, and image biomarkers improves noninvasive diagnosis of patients with IPNs, potentially reducing the rate of unnecessary invasive procedures while shortening the time to diagnosis.

25 May 2023 in Chest
Verified
Journal Article
Closed access
RPRafael Paez
Rafael Paez
MKMichael Nolan Kammer
Michael Nolan Kammer
NTNicole T. Tanner
Nicole T. Tanner
SSSamira Shojaee
Samira Shojaee
BHBrent E. Heideman
Brent E. Heideman
FMFabien Maldonado
Fabien Maldonado

1 February 2023 in Current Challenges in Thoracic Surgery
Verified
Journal Article
Open access
PDF file
HMHannah N. Marmor
Hannah N. Marmor
JZJ. Tyler Zorn
J. Tyler Zorn
SDStephen A. Deppen
Stephen A. Deppen
PMPierre P. Massion
Pierre P. Massion
EGEric L Grogan
Eric L Grogan
Although when used as a lung cancer screening tool low-dose computed tomography (LDCT) has demonstrated a significant reduction in lung cancer related mortality, it is not without pitfalls. The associated high false positive rate, inability to distinguish between benign and malignant nodules, cumulative radiation exposure, and resulting patient anxiety have all demonstrated the need for adjunctive testing in lung cancer screening. Current research focuses on developing liquid biomarkers to complement imaging as non-invasive lung cancer diagnostics. Biomarkers can be useful for both the early detection and diagnosis of disease, thereby decreasing the number of unnecessary radiologic tests performed. Biomarkers can stratify cancer risk to further enrich the screening population and augment existing risk prediction. Finally, biomarkers can be used to distinguish benign from malignant nodules in lung cancer screening. While many biomarkers require further validation studies, several, including autoantibodies and blood protein profiling, are available for clinical use. This paper describes the need for biomarkers as a lung cancer screening tool, both in terms of diagnosis and risk assessment. Additionally, this paper will discuss the goals of biomarker use, describe properties of a good biomarker, and review several of the most promising biomarkers currently being studied including autoantibodies, complement fragments, microRNA, blood proteins, circulating tumor DNA (ctDNA), and DNA methylation. Finally, we will describe future directions in the field of biomarker development.

11 January 2023 in Science Translational Medicine
Verified
Journal Article
Open access
KLKristin J. Lastwika
Kristin J. Lastwika
AKAndrew Kunihiro
Andrew Kunihiro
JSJoell L. Solan
Joell L. Solan
YZYuzheng Zhang
Yuzheng Zhang
LTLydia R. Taverne
Lydia R. Taverne
PLPaul Lampe
Paul Lampe
Small cell lung cancer (SCLC) elicits the generation of autoantibodies that result in unique paraneoplastic neurological syndromes. The mechanistic basis for the formation of such autoantibodies is largely unknown but is key to understanding their etiology. We developed a high-dimensional technique that enables detection of autoantibodies in complex with native antigens directly from patient plasma. Here, we used our platform to screen 1009 human plasma samples for 3600 autoantibody-antigen complexes, finding that plasma from patients with SCLC harbors, on average, fourfold higher disease-specific autoantibody signals compared with plasma from patients with other cancers. Across three independent SCLC cohorts, we identified a set of common but previously unknown autoantibodies that are produced in response to both intracellular and extracellular tumor antigens. We further characterized several disease-specific posttranslational modifications within extracellular proteins targeted by these autoantibodies, including citrullination, isoaspartylation, and cancer-specific glycosylation. Because most patients with SCLC have metastatic disease at diagnosis, we queried whether these autoantibodies could be used for SCLC early detection. We created a risk prediction model using five autoantibodies with an average area under the curve of 0.84 for the three cohorts that improved to 0.96 by incorporating cigarette smoke consumption in pack years. Together, our findings provide an innovative approach to identify circulating autoantibodies in SCLC with mechanistic insight into disease-specific immunogenicity and clinical utility.

4 July 2023 in Chest
Verified
Journal Article
Closed access
CGCaroline M. Godfrey
Caroline M. Godfrey
MSMaren E. Shipe
Maren E. Shipe
VWValerie F. Welty
Valerie F. Welty
AMAmelia W. Maiga
Amelia W. Maiga
MAMelinda C. Aldrich
Melinda C. Aldrich
EGEric L Grogan
Eric L Grogan